Search

Your search keyword '"Bizollon, T."' showing total 143 results
Start Over Author "Bizollon, T."
143 results on '"Bizollon, T."'

2. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. (Liver Disease)

Author

Bizollon, T., Ahmed, S.N.S, Radenne, S., Chevallier, M., Chevallier, P., Parvaz, P., Guichard, S., Ducerf, C., Baulieux, J., Zoulim, F., and Trepo, C.

Subjects
Interferon -- Evaluation, Ribavirin -- Evaluation, Hepatitis C -- Drug therapy, Health
Abstract

Background and objective: A proportion of liver transplanted patients with recurrent chronic hepatitis have a sustained virological response to combination therapy with interferon plus ribavirin. However, the long term benefit [...]

Published
2003

17. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

Author

Schiff, E, Lai, C, Hadziyannis, S, Nuehaus, P, Terrault, N, Colombo, M, Tillmann, H, Samuel, D, Zuezem, S, Villenueve, J, Arteburn, S, Borroto-Esoda, K, Brosgart, C, Chuck, S, Shakil, A, Fung, J, Alberti, A, Lok, A, Picciotto, A, Torre, F, Riely, C, Trepo, C, Bizollon, T, Bottaa-Fridlund, D, Gerolami, R, Douglas, D, Ranjan, D, Faust, D, Trojan, J, Gane, E, Villa, E, Boarino, M, Sokal, E, Starkel, P, Bonino, F, Maurizio, B, Gordon, F, Pratt, J, Berr, F, Schiefke, I, Mccaughan, G, Strasser, S, Dusheiko, G, Pageaux, G, Larrey, D, Pastore, G, Santantonio, T, Alexander, G, Woodall, T, Van Vlierberghe, H, Colle, I, Harley, H, Guggenheim, J, Myx-Staccini, A, Metreau, J, Mavier, P, Vierling, J, Tran, T, Girgrah, N, Nyberg, L, Yuen, M, Ma, M, Balnco, M, Merli, M, Tanzilli, P, Angelico, M, Di Paolo, D, Rizzetto, M, Marzano, A, Lampertico, P, Prieto, M, Berenguer, M, Felder, M, Sterneck, M, Willems, M, Charlton, M, Gunneson, T, Ritter, M, Voight, M, Swift, J, Shiffman, M, Tassopoulos, N, Klissas, I, Naourmov, N, Chamouard, P, Marcellin, P, Durand, F, Angus, P, Nathan, C, Toniutto, P, Fumo, E, Andreone, P, Cursaro, C, Barcena, R, Hoz, F, Zachoval, R, Christina, M, De Man, R, Metselaar, H, Fagiuoli, S, Schiff E., Lai C. -L., Hadziyannis S., Nuehaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zuezem S., Villenueve J. -P., Arteburn S., Borroto-Esoda K., Brosgart C., Chuck S., Shakil A. O., Fung J., Alberti A., Lok A., Picciotto A., Torre F., Riely C., Trepo C., Bizollon T., Bottaa-Fridlund D., Gerolami R., Douglas D., Ranjan D., Faust D., Trojan J., Gane E., Villa E., Boarino M., Sokal E., Starkel P., Bonino F., Maurizio B., Gordon F., Pratt J., Berr F., Schiefke I., McCaughan G., Strasser S., Dusheiko G., Pageaux G. P., Larrey D., Pastore G., Santantonio T., Alexander G., Woodall T., Van Vlierberghe H., Colle I., Harley H., Guggenheim J., Myx-Staccini A., Metreau J. M., Mavier P., Vierling J., Tran T., Girgrah N., Nyberg L., Yuen M. -F., Ma M., Balnco M. D., Merli M., Tanzilli P., Angelico M., Di Paolo D., Rizzetto M., Marzano A., Lampertico P., Prieto M., Berenguer M., Felder M., Sterneck M., Willems M., Charlton M., Gunneson T., Ritter M., Voight M., Swift J., Shiffman M., Tassopoulos N., Klissas I., Naourmov N., Chamouard P., Marcellin P., Durand F., Angus P., Nathan C., Toniutto P., Fumo E., Andreone P., Cursaro C., Barcena R., Hoz F. G., Zachoval R., Christina M., De Man R. A., Metselaar H., Fagiuoli S., Schiff, E, Lai, C, Hadziyannis, S, Nuehaus, P, Terrault, N, Colombo, M, Tillmann, H, Samuel, D, Zuezem, S, Villenueve, J, Arteburn, S, Borroto-Esoda, K, Brosgart, C, Chuck, S, Shakil, A, Fung, J, Alberti, A, Lok, A, Picciotto, A, Torre, F, Riely, C, Trepo, C, Bizollon, T, Bottaa-Fridlund, D, Gerolami, R, Douglas, D, Ranjan, D, Faust, D, Trojan, J, Gane, E, Villa, E, Boarino, M, Sokal, E, Starkel, P, Bonino, F, Maurizio, B, Gordon, F, Pratt, J, Berr, F, Schiefke, I, Mccaughan, G, Strasser, S, Dusheiko, G, Pageaux, G, Larrey, D, Pastore, G, Santantonio, T, Alexander, G, Woodall, T, Van Vlierberghe, H, Colle, I, Harley, H, Guggenheim, J, Myx-Staccini, A, Metreau, J, Mavier, P, Vierling, J, Tran, T, Girgrah, N, Nyberg, L, Yuen, M, Ma, M, Balnco, M, Merli, M, Tanzilli, P, Angelico, M, Di Paolo, D, Rizzetto, M, Marzano, A, Lampertico, P, Prieto, M, Berenguer, M, Felder, M, Sterneck, M, Willems, M, Charlton, M, Gunneson, T, Ritter, M, Voight, M, Swift, J, Shiffman, M, Tassopoulos, N, Klissas, I, Naourmov, N, Chamouard, P, Marcellin, P, Durand, F, Angus, P, Nathan, C, Toniutto, P, Fumo, E, Andreone, P, Cursaro, C, Barcena, R, Hoz, F, Zachoval, R, Christina, M, De Man, R, Metselaar, H, Fagiuoli, S, Schiff E., Lai C. -L., Hadziyannis S., Nuehaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zuezem S., Villenueve J. -P., Arteburn S., Borroto-Esoda K., Brosgart C., Chuck S., Shakil A. O., Fung J., Alberti A., Lok A., Picciotto A., Torre F., Riely C., Trepo C., Bizollon T., Bottaa-Fridlund D., Gerolami R., Douglas D., Ranjan D., Faust D., Trojan J., Gane E., Villa E., Boarino M., Sokal E., Starkel P., Bonino F., Maurizio B., Gordon F., Pratt J., Berr F., Schiefke I., McCaughan G., Strasser S., Dusheiko G., Pageaux G. P., Larrey D., Pastore G., Santantonio T., Alexander G., Woodall T., Van Vlierberghe H., Colle I., Harley H., Guggenheim J., Myx-Staccini A., Metreau J. M., Mavier P., Vierling J., Tran T., Girgrah N., Nyberg L., Yuen M. -F., Ma M., Balnco M. D., Merli M., Tanzilli P., Angelico M., Di Paolo D., Rizzetto M., Marzano A., Lampertico P., Prieto M., Berenguer M., Felder M., Sterneck M., Willems M., Charlton M., Gunneson T., Ritter M., Voight M., Swift J., Shiffman M., Tassopoulos N., Klissas I., Naourmov N., Chamouard P., Marcellin P., Durand F., Angus P., Nathan C., Toniutto P., Fumo E., Andreone P., Cursaro C., Barcena R., Hoz F. G., Zachoval R., Christina M., De Man R. A., Metselaar H., and Fagiuoli S.

Abstract

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (

Published
2007

18. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

Author

Schiff E., Lai C. -L., Hadziyannis S., Nuehaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zuezem S., Villenueve J. -P., Arteburn S., Borroto-Esoda K., Brosgart C., Chuck S., Shakil A. O., Fung J., Alberti A., Lok A., Picciotto A., Torre F., Riely C., Trepo C., Bizollon T., Bottaa-Fridlund D., Gerolami R., Douglas D., Ranjan D., Faust D., Trojan J., Gane E., Villa E., Boarino M., Sokal E., Starkel P., Bonino F., Maurizio B., Gordon F., Pratt J., Berr F., Schiefke I., McCaughan G., Strasser S., Dusheiko G., Pageaux G. P., Larrey D., Pastore G., Santantonio T., Alexander G., Woodall T., Van Vlierberghe H., Colle I., Harley H., Guggenheim J., Myx-Staccini A., Metreau J. M., Mavier P., Vierling J., Tran T., Girgrah N., Nyberg L., Yuen M. -F., Ma M., Balnco M. D., Merli M., Tanzilli P., Angelico M., Di Paolo D., Rizzetto M., Marzano A., Lampertico P., Prieto M., Berenguer M., Felder M., Sterneck M., Willems M., Charlton M., Gunneson T., Ritter M., Voight M., Swift J., Shiffman M., Tassopoulos N., Klissas I., Naourmov N., Chamouard P., Marcellin P., Durand F., Angus P., Nathan C., Toniutto P., Fumo E., Andreone P., Cursaro C., Barcena R., Hoz F. G., Zachoval R., Christina M., De Man R. A., Metselaar H., Fagiuoli S., Schiff, E, Lai, C, Hadziyannis, S, Nuehaus, P, Terrault, N, Colombo, M, Tillmann, H, Samuel, D, Zuezem, S, Villenueve, J, Arteburn, S, Borroto-Esoda, K, Brosgart, C, Chuck, S, Shakil, A, Fung, J, Alberti, A, Lok, A, Picciotto, A, Torre, F, Riely, C, Trepo, C, Bizollon, T, Bottaa-Fridlund, D, Gerolami, R, Douglas, D, Ranjan, D, Faust, D, Trojan, J, Gane, E, Villa, E, Boarino, M, Sokal, E, Starkel, P, Bonino, F, Maurizio, B, Gordon, F, Pratt, J, Berr, F, Schiefke, I, Mccaughan, G, Strasser, S, Dusheiko, G, Pageaux, G, Larrey, D, Pastore, G, Santantonio, T, Alexander, G, Woodall, T, Van Vlierberghe, H, Colle, I, Harley, H, Guggenheim, J, Myx-Staccini, A, Metreau, J, Mavier, P, Vierling, J, Tran, T, Girgrah, N, Nyberg, L, Yuen, M, Ma, M, Balnco, M, Merli, M, Tanzilli, P, Angelico, M, Di Paolo, D, Rizzetto, M, Marzano, A, Lampertico, P, Prieto, M, Berenguer, M, Felder, M, Sterneck, M, Willems, M, Charlton, M, Gunneson, T, Ritter, M, Voight, M, Swift, J, Shiffman, M, Tassopoulos, N, Klissas, I, Naourmov, N, Chamouard, P, Marcellin, P, Durand, F, Angus, P, Nathan, C, Toniutto, P, Fumo, E, Andreone, P, Cursaro, C, Barcena, R, Hoz, F, Zachoval, R, Christina, M, De Man, R, Metselaar, H, and Fagiuoli, S

Subjects
Male, medicine.medical_treatment, Liver transplantation, medicine.disease_cause, Gastroenterology, lamivudine-resistant, chemistry.chemical_compound, antiviral therapy, Secondary Prevention, Adefovir, Prospective Studies, Adefovir dipivoxil, medicine.diagnostic_test, liver transplantation, Lamivudine, Middle Aged, Hepatitis B, Drug Therapy, Combination, Female, Kidney Diseases, medicine.drug, Adult, medicine.medical_specialty, Waiting Lists, Adenine, Antiviral Agents, DNA, Viral, Drug Resistance, Viral, Hepatitis B virus, Humans, Liver Transplantation, Organophosphonates, Bilirubin, Internal medicine, medicine, wait-listed, hepatitis B virus, Prothrombin time, Transplantation, Hepatology, business.industry, medicine.disease, chemistry, Immunology, Surgery, hepatitis B, business
Abstract

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (

Published
2007

21. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/CHIR - Département de chirurgie, Feray, C, Lerut, Jan, Caccamo, L, Alexander, GJM., Ducot, B, Gugenheim, J, Casanovas, T, Loinaz, C, Gigou, M, Burra, P., Barkholt, L, Esteban, R, Bizollon, T, Minello-Franza, A, Bernard, PH, Nachbaur, G, Botta-Fridlund, D, Bismuth, H, Schalm, SW, Samuel, D, UCL - Cliniques universitaires Saint-Luc, UCL - MD/CHIR - Département de chirurgie, Feray, C, Lerut, Jan, Caccamo, L, Alexander, GJM., Ducot, B, Gugenheim, J, Casanovas, T, Loinaz, C, Gigou, M, Burra, P., Barkholt, L, Esteban, R, Bizollon, T, Minello-Franza, A, Bernard, PH, Nachbaur, G, Botta-Fridlund, D, Bismuth, H, Schalm, SW, and Samuel, D

Abstract

Background & Aims: Liver transplantation for hepatitis C virus (HCV)-related liver disease is characterized by frequent graft infection by HCV. The prognosis and risk factors for morbidity and mortality in this condition were determined. Methods: A retrospective study of 652 consecutive anti-HCV-positive patients undergoing liver transplantation between 1984 and 1995 in 15 European centers was conducted; 102 patients coinfected with hepatitis B virus (HBV) received immunoglobulin prophylaxis for antibody to hepatitis B surface antigen. Results: Overall, 5-year survival was 72%. Five-year actuarial rates of hepatitis and cirrhosis were 80% and 10%. Genotypes 1b, 1a, and 2 were detected in 214 (80%), 24 (9%), and 24 (9%) of 268 patients analyzed. The only discriminant factor for patient or graft survival was hepatocellular carcinoma as primary indication. Independent risk factors for recurrent hepatitis included the absence of HBV coinfection before transplantation (relative risk [RR], 1.7; 95% confidence interval [CI], 1.2-2.6; P = 0.005), genotype Ib (RR, 2; 95% CI, 1.3-2.9; P = 0.01), and age > 49 years (RR, 1.4; 95% CI, 1.1-1.8; P = 0.01). Conclusions: The results of transplantation for HCV-related disease are compromised by a significant risk of cirrhosis, although 5-year survival is satisfactory. Genotype 1b, age, and absence of pretransplantation coinfection by HBV are risk factors for recurrent HCV.

Published
1999

36. Correction of acute liver cell failure disorders through liver xenoperfusion: Experimental study

Author

Adham, M., primary, Sab, J.M., additional, Ducerf, C., additional, Tassaux, D., additional, Vianey-Saban, C., additional, Chevallier, M., additional, de la Roche, E., additional, Le, Q.V., additional, Bizollon, T., additional, Barakat, C., additional, Debize, G., additional, Vernet, M., additional, Pouyet, M., additional, and Baulieux, J., additional

Published
1997
Full Text
View/download PDF

43. Hepatic outflow study after piggyback liver transplantation

Author

Ducerf, C., Rode, A., Adham, M., Roche, E.D.l., Bizollon, T., Baulieux, J., and Pouyet, M.

Abstract

Background. Hepatic vein outflow is discussed in liver transplantation after preservation of recipient retrohepatic vena cava. The aim of this study was to compare two methods of suparahepatic caval anastomosis. Methods. From January 1993 to January 1995, 81 patients received 88 liver transplants because of liver cirrhosis (n=70), acute liver failure (n=7), elective retransplantation after hepatic artery thrombosis (n=2), giant hemangioma (n=1), and combined liver-small bowel transplantation (n=1). Seven patients underwent urgent retransplantation, 12 had preoperative transjugular intrahepatic portacaval stent, and 11 had portal vein thrombosis. Five patients required extracorporeal venous shunt. A total of 82 liver transplantations had preservation of RHVC, and 70 patients received temporary end-to-side portacaval shunt. Suprahepatic caval anastomosis was carried out in 52 patients (group 1) between the graft suprahepatic vena cava and the ostia of recipient left and median hepatic veins. Thirty patients (group 2) had associated 3 cm vertical cavotomy with partial clamping of RHVC. In the fourth postoperative month 20 patients from each group had pressure and gradient measurement made among the hepatic veins, right atria, and the RHVC. Results. Mean pressure gradient between hepatic veins and right atria was 0.75+/-0.49 mm Hg in group 1 and 2.06+/-0.85 mm Hg in group 2. Between the RHVC and the right atria it was 0.63+/-0.5 mm Hg in group 1 and 2.22+/-1.29 mm Hg in group 2. A pressure gradient higher than 3 mm Hg was considered hemodynamically significant. This pressure gradient was found between the hepatic veins and right atria in 10% of patients in group 1 and 40% of patients in group 2 (p=0.03) and between the RHVC and right atria in 15% of patients in group 1 and 30% of patients in group 2 (p=0.3). Conclusions. Preservation of the recipient RHVC with recipient caval anastomosis at the ostia of the median and left hepatic veins is a reliable technique without any hepatic venous outflow alteration. Associated cavotomy is not necessary.

Published
1996
Full Text
View/download PDF

47. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

Author

Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, Souquet JC, Ducerf C, Baulieux J, Zoulim F, and Trepo C

Subjects
Adult, Aged, Carcinoma, Hepatocellular etiology, Drug Therapy, Combination, Female, Humans, Liver pathology, Liver Cirrhosis etiology, Liver Neoplasms etiology, Male, Middle Aged, RNA, Viral analysis, Recurrence, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Graft Survival physiology, Hepacivirus drug effects, Hepatitis C, Chronic drug therapy, Interferons therapeutic use, Liver Transplantation, Ribavirin therapeutic use
Abstract

Recurrent hepatitis C infection is an important cause of progressive fibrosis, cirrhosis and graft loss after liver transplantation. Treatment for post-transplant recurrence results in sustained virological response (SVR) in up to 30% of cases. The aim of this study was to evaluate the impact of SVR on patients and graft survival. Thirty-four patients with an SVR to IFN-ribavirin were included. Forty-six nonresponders to the combination formed the control group. Follow-up data were recorded every 6 months and included HCV RNA, and the occurrence of clinical problems (cirrhosis, decompensation, hepatocellular carcinoma, death). A graft biopsy was performed every year. The mean follow-up duration was 52 months in responders and 57 months in nonresponders. Two patients died in each group of patients. Two patients with SVR developed late virological relapse. Fibrosis decreased in 38% of patients with SVR, remained stable in 44% and worsened in 18%. In contrast, fibrosis increased in the majority of nonresponder patients (74%, p<0.001). At the end of follow-up, no patient without cirrhosis at inclusion developed cirrhosis of the graft versus 9 among nonresponder patients (p=0.009). No difference in patient survival was observed in the two groups. In conclusion, this study shows that HCV eradication has a positive impact on graft survival.

Published
2005
Full Text
View/download PDF

48. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.

Author

Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J, Zoulim F, and Trepo C

Subjects
Adult, Blood Cell Count, Drug Therapy, Combination, Female, Hepacivirus isolation & purification, Humans, Immunosuppressive Agents therapeutic use, Interferon alpha-2, Male, Middle Aged, Postoperative Complications prevention & control, RNA, Viral blood, Recombinant Proteins, Recurrence, Survival Analysis, Amantadine therapeutic use, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Hepatitis C surgery, Interferon-alpha therapeutic use, Liver Transplantation mortality, Postoperative Complications virology, Ribavirin therapeutic use
Abstract

Background: HCV reinfection after liver transplantation is universal and has an accelerated course with a high risk of progression to cirrhosis. It is now established that combination therapy with interferon (IFN) alpha and ribavirin may achieve a sustained virological response in 20% of transplanted patients. However, the optimal therapy for nonresponders remains an unresolved issue. We conducted a pilot study to determine the efficacy and safety of triple antiviral therapy in IFN-ribavirin nonresponders with recurrent chronic hepatitis C., Methods: Twenty-four nonresponders to the IFN-ribavirin combination were enrolled in this pilot study. Patients were treated with IFN-alpha (3 million units three times a week subcutaneously with ribavirin [800-1,000 mg daily]) and amantadine 200 mg daily for 48 weeks. The primary end point was the loss of HCV RNA 6 months after the end of treatment., Results: Median age was 50 years; 72% were men and 82% had genotype 1. The median interval between the end of combination therapy and enrollment was 11 months. Twenty-four patients started therapy, but five (21%) withdrew due to side effects, including two with anemia. On an intent-to-treat basis, 18 patients (75%) had a biochemical response and 9 (37%) had a virologic response at the end of triple antiviral therapy. Eight of these nine patients (33%) had a sustained virological response. The mean METAVIR score improved from A 2.2 F2.1 before treatment to A 1.2 F1.9 in sustained virological responders. In virological nonresponders, inflammatory activity did not change, but fibrosis worsened. Several patients required treatment with erythropoietin for anemia. Triple therapy was well tolerated and neither increased the frequency nor severity of side effects., Conclusion: Our results show that triple antiviral therapy for 48 weeks induced a sustained virological response in 33% of IFN-ribavirin nonresponders with recurrent hepatitis C.

Published
2005
Full Text
View/download PDF

49. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

Author

Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, and Trepo C

Subjects
Alanine Transaminase blood, Antiviral Agents adverse effects, Drug Therapy, Combination, Female, Hepacivirus genetics, Hepatitis C, Chronic blood, Hepatitis C, Chronic pathology, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, RNA, Viral blood, Recombinant Proteins, Recurrence, Ribavirin adverse effects, Safety, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic surgery, Interferon-alpha therapeutic use, Liver Transplantation, Postoperative Care, Ribavirin therapeutic use
Abstract

Background and Aims: Hepatitis C virus (HCV) reinfection after liver transplantation is frequent and leads to chronic hepatitis and cirrhosis. The use of antiviral therapy in this situation remains controversial. This study aimed to assess the safety and efficacy of interferon alfa-2b plus ribavirin for recurrent hepatitis C following liver transplantation., Methods: Transplant recipients with recurrent chronic hepatitis C were randomized to receive either no treatment or therapy with interferon alfa-2b (3 MU 3 times a week) plus 1000-1200 mg/day ribavirin for 1 year. Patients were followed up for 6 months after the end of treatment. The primary end point was loss of HCV RNA 6 months after the end of treatment., Results: Fifty-two patients were randomized (treatment, 28; placebo, 24). Sixteen patients were withdrawn from the study; 12 (43%) were from the treated group (mainly for anemia [7 patients]) and 4 (17%) from the control group. In the treated group, serum HCV RNA was undetectable in 9 patients (32%) at the end of treatment and 6 (21.4%) at the end of the follow-up period, whereas no patient in the control group lost HCV RNA at any point (P = 0.036 at the end of follow-up). However, there was no significant histologic improvement., Conclusions: The combination of interferon alfa-2b plus ribavirin induced a sustained virologic response in 21% of transplant recipients with recurrent hepatitis C. However, 43% discontinued therapy due to adverse events (primarily severe anemia). Strategies to enable treatment with lower doses of ribavirin need to be explored.

Published
2003
Full Text
View/download PDF

50. [Intussusception of the small intestine due to Peutz-Jeghers syndrome: a case report and review of the literature].

Author

Cherki S, Adham M, Bizollon T, Gaudin JL, and Baulieux J

Subjects
Humans, Intussusception diagnostic imaging, Intussusception surgery, Jejunal Diseases diagnostic imaging, Jejunal Diseases surgery, Male, Middle Aged, Peutz-Jeghers Syndrome diagnostic imaging, Peutz-Jeghers Syndrome surgery, Risk Factors, Tomography, X-Ray Computed, Intussusception etiology, Jejunal Diseases etiology, Peutz-Jeghers Syndrome complications
Abstract

One case of small bowel's intussuception has been found in one patient with abdominal pains. Since 13 years this patient has a Peutz-Jeghers syndrome. A resection of the small bowel has been performed followed by total intraoperative enteroscopy. Besides small bowel, Peutz-Jeghers syndrome can affect many organs with an increased risk for cancer for patients affected by this genetic disease.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results